Eisai postpones NerBloc launch
NerBloc, a botulinum toxin type B neuromuscular-blocking agent, has been approved by the Japanese regulatory authority in 21 January 2011. NerBloc has showed improvement in TWSTRS (Toronto Western
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.